New OxThera/Oxabact Us Patent Granted (Cision News)

New OxThera/Oxabact US Patent Granted

UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.

The first formulation of Oxabact was patented and granted back in 1999. Since 2012, the company has developed a new, high-concentrated formulation of Oxabact designed to promote excretion of endogenous oxalate from blood plasma. The new formulation of Oxabact is under final Phase 3 clinical testing in patients with Primary Hyperoxaluria.

“We are happy to announce that our Oxabact product now has another 20 years of patent coverage in the US,” said Matthew Gantz, CEO of OxThera. “Oxabact has great potential to become a new treatment for hyperoxaluria.”

Learn more about New OxThera/Oxabact US Patent Granted.
Related news OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact in Patients With Primary Hyperoxaluria.